London - British pharmaceuticals giant AstraZeneca faces a clash with its shareholders amid mounting disappointment at its rejection of a sweetened takeover offer by Pfizer.
"We are extremely disappointed with the turn of events at Astra on Monday," said one - a fund manager at a top 10 investor in AstraZeneca after the company rebuffed a raised takeover offer of £55 a share, worth about £70bn.
Entrenched opposition
"We do not think the Astra management have done a good job on behalf of shareholders.
"We had already urged Astra to engage in discussions with Pfizer," added the fund manager.
Pfizer had sought to create the world's largest drugs company but met entrenched opposition from AstraZeneca, while many British politicians and scientists had expressed worries about cuts to jobs and research in Britain.
Shares in AstraZeneca were trading more than 10% lower after it rejected Pfizer's "final" offer.
Recommend
A second AstraZeneca shareholder within the 40 largest investors in the company said surprise at the rejected offer was widespread among his peers.
"I thought at 55 they'd say 'lets open the books and chat' so I think large numbers of shareholders out there will be disappointed," the second shareholder said.
AstraZeneca chairperson Leif Johansson said he had made clear in discussions with Pfizer that his board could only recommend a bid that was at least 10% above an offer of £53.50 made by Pfizer on Friday, or £58.85.